Tongjitang Pins Loss On Delayed Implementation Of China's Essential Drug List; Proposed Buyout Still Under Review

SHANGHAI - Tongjitang, the first traditional Chinese medicine company listed on the New York Stock Exchange, reported a $694,000 net loss during the second quarter for the year, attributing it to increased sales and marketing expenses for sales infrastructure and its essential drug sales network